Attached files
file | filename |
---|---|
EX-10.71 - SCHEDULE OF AMENDMENTS TO OMITTED CREDIT AGREEMENTS - PDL BIOPHARMA, INC. | pdli1231201510-kex1071.htm |
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - PDL BIOPHARMA, INC. | pdli1231201510-kex211.htm |
EX-23.2 - CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - PDL BIOPHARMA, INC. | pdli1231201510-kex232.htm |
EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli1231201510-kex321.htm |
EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli1231201510-kex312.htm |
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - PDL BIOPHARMA, INC. | pdli1231201510-kex231.htm |
10-K - 10-K - PDL BIOPHARMA, INC. | pdli1231201510-kdoc.htm |
EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli1231201510-kex311.htm |
Exhibit 12.1
PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)
For the Years Ended December 31, | ||||||||||||||||||||
2011 | 2012 | 2013 | 2014 | 2015 | ||||||||||||||||
Earnings: | ||||||||||||||||||||
Income before income taxes | $ | 307,428 | $ | 327,133 | $ | 401,876 | $ | 501,272 | $ | 530,138 | ||||||||||
Add: fixed charges | 36,153 | 29,097 | 24,931 | 39,274 | 27,123 | |||||||||||||||
Earnings | $ | 343,581 | $ | 356,230 | $ | 426,807 | $ | 540,546 | $ | 557,261 | ||||||||||
Fixed Charges: | ||||||||||||||||||||
Interest expense1 | $ | 36,102 | $ | 29,036 | $ | 24,871 | $ | 39,211 | $ | 27,059 | ||||||||||
Estimated interest portion of rent expense2 | 51 | 61 | 60 | 63 | 64 | |||||||||||||||
Fixed charges | $ | 36,153 | $ | 29,097 | $ | 24,931 | $ | 39,274 | $ | 27,123 | ||||||||||
Ratio of earnings to fixed charges | 9.50 | 12.24 | 17.12 | 13.76 | 20.55 |
_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.